Gland Pharma and Neuland Laboratories announce strategic sterile API manufacturing partnership
Gland Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Partnership announced on August 5, 2026, to establish a sterile manufacturing suite for APIs related to microparticle depot products
- Gland Pharma to expand sterile manufacturing at JNPC facility, Visakhapatnam, adding approx. 1400 kg annual capacity to meet global sterile API demand
- Collaboration leverages Neuland's complex API expertise and Gland's sterile manufacturing, operating under cGMP, USFDA, and EU standards.
Why it's rated notable: The filing announces a long-term sterile API partnership and a new suite adding about 1400 kg of annual capacity, but states no contract value or capex amount, so the level stays at medium.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.